Quarterly report pursuant to Section 13 or 15(d)

Revenue - Potential Milestone Payments (Details)

v3.22.1
Revenue - Potential Milestone Payments (Details) - Strategic Partnerships and Other License Agreements
$ in Millions
Mar. 31, 2022
USD ($)
Research, Development, Regulatory & Commercial Milestones  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments $ 2,719
Research, Development, Regulatory & Commercial Milestones | AstraZeneca  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 900
Research, Development, Regulatory & Commercial Milestones | Servier  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 133
Research, Development, Regulatory & Commercial Milestones | Seagen  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 754
Research, Development, Regulatory & Commercial Milestones | Boston Pharmaceuticals  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 88
Research, Development, Regulatory & Commercial Milestones | Genentech  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 844
Sales Milestones  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 5,515
Sales Milestones | AstraZeneca  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 4,100
Sales Milestones | Servier  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 100
Sales Milestones | Seagen  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 450
Sales Milestones | Boston Pharmaceuticals  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 265
Sales Milestones | Genentech  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments $ 600